-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>
This study (NCT05164458) is an open-label, multicenter Phase 1a/1b study evaluating the safety, tolerability and efficacy of IBI389 in the treatment of advanced malignant tumors.
Bispecific antibodies targeting CD3 (CD3-BsAbs) or T Cell Engager (TCE) antibodies are emerging treatments in the field of cancer immunotherapy in recent years
The main researcher of the study, Professor Bi Feng, director of the Department of Abdominal Oncology and Director of the Research Office of Molecular Targeted Therapy of Tumors, West China Hospital of Sichuan University, pointed out: " In recent years, CLDN18.
Dr.
About IBI389
IBI389 is an anti-CLDN18.
About Claudin 18.
Claudin protein is a key component of tight junction complex molecules, and tight junctions play an important role in the life activities of the human body
Globally, a number of candidate therapies are in clinical development, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR-T cell products
About Stomach and Pancreatic Cancer
Gastric cancer and pancreatic cancer are both malignant tumors of the digestive system that seriously endanger human life and health
About Innovent
" Begins with faith, achieves in action " and develops high-quality biological medicines that the common people can afford, which is the ideal and goal of Innovent Bio
Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model
Innovent Bio has established a high-end biopharmaceutical development and industrialization talent team with international advanced level, including many returnee experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center and Hanmi in South Korea.
For details, please visit the company's website:or the company's LinkedIn account: Innovent Biologics
statement:
1.
Forward-Looking Statements
Information published in this press release may contain certain forward-looking statements
These forward-looking statements are based on the Company's management's current beliefs, assumptions, expectations, estimates, projections and understanding of future events at the time the statements are made
.
These statements are not guarantees for future development and are subject to risks, uncertainties and other factors, some of which are beyond the control of the company and are difficult to predict
.
Accordingly, actual results may differ materially from those contained in forward-looking statements as a result of future changes and developments in our business, competitive environment, political, economic, legal and social conditions
.
The Company, its directors and employee agents disclaim (a) any obligation to correct or update the forward-looking statements contained in this website; and (b) if any forward-looking statement does not materialize or becomes incorrect responsibility
.
